6-chloro-2-phenoxy-1,3-benzothiazole | 1179324-90-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-chloro-2-phenoxy-1,3-benzothiazole
• 英文别名: 6-chloro-2-phenoxybenzo[d]thiazole；2-Phenoxy-6-chlorobenzothiazole
• CAS: 1179324-90-3
• 化学式: C₁₃H₈ClNOS
• 分子量: 261.732
• InChiKey: UWSHJNMVLKXMHO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-Chloro-2-iodophenyl Isothiocyanate 、 苯酚 在 copper(l) iodide 、 1,10-菲罗啉 、 potassium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 反应 12.0h， 以78%的产率得到6-chloro-2-phenoxy-1,3-benzothiazole
  参考文献：
  名称：

  铜 (I) 催化的 2-取代 1,3-苯并噻唑级联合成：直接获得苯并噻唑酮

  摘要：

  已经开发出一种通过 Cu 催化的分子内 C-S 键形成直接从 2-卤代芳基异硫氰酸酯和 O 或 S 亲核试剂制备 2-取代 1,3-苯并噻唑的高效级联工艺。这种级联方法对于 O-和 S-取代的 1,3-苯并噻唑的有效合成是可行的。此外，具有烷基的 1,3-苯并噻唑-2(3H)-酮易于获得 1,3-苯并噻唑酮。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2009)

  DOI：

  10.1002/ejoc.200900711

文献信息

• COMPOSITIONS AND METHODS FOR DRUG SENSITIZATION OF PARASITES
  申请人：The Texas A&M University System

  公开号：EP3659597A2

  公开（公告）日：2020-06-03

  The present invention relates to arylphenoxypropionate derivatives, aryloxyphenoxyacetate derivatives, aryloxyphenylacetate derivatives, substituted quinols, or pharmaceutically acceptable salts, hydrates, or prodrugs thereof, or combinations thereof that can be used in the inhibition of parasites.

  本发明涉及可用于抑制寄生虫的芳基苯氧基丙酸酯衍生物、芳基苯氧基乙酸酯衍生物、芳基苯氧基乙酸酯衍生物、取代喹啉，或其药学上可接受的盐、水合物或原药，或其组合。
• Compositions and methods for inhibition of mycobacteria
  申请人：The Texas A&M University System

  公开号：US10300071B2

  公开（公告）日：2019-05-28

  A composition comprising a drug selected from the group consisting of an arylphenoxypropionate derivative, an aryloxyphenoxyacetate derivative, an aryloxyphenylacetate derivative, a substituted quinol, or a salt, hydrate, or prodrugs thereof, or a combination thereof, in an amount and formulation sufficient to inhibit a mycobacterium is disclosed.

  本发明公开了一种组合物，该组合物包含一种选自由芳基苯氧基丙酸酯衍生物、芳氧基苯氧基乙酸酯衍生物、芳氧基苯乙酸酯衍生物、取代喹啉或其盐、水合物或原药或其组合组成的组的药物，其用量和制剂足以抑制分枝杆菌。
• Compositions and methods for drug sensitization of parasites
  申请人：The Texas A&M University System

  公开号：US10543200B2

  公开（公告）日：2020-01-28

  Compositions and methods for inhibiting and/or sensitizing or re-sensitizing a parasite to an antiparasitic drug are provided. The compositions can comprise a an arylphenoxypropionate derivative, an aryloxyphenoxyacetate derivative, an aryloxyphenylacetate derivative, one or more substituted quinols, or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, or a combination thereof in an amount and formulation sufficient to sensitize the parasite to the drug, treating infection of a patient by a parasite with a drug, or to prevent symptomatic infection of a patient by a parasite with a drug.

  提供了抑制寄生虫和/或使寄生虫对抗寄生虫药物敏感或再敏感的组合物和方法。这些组合物可以包括芳基苯氧基丙酸酯衍生物、芳基氧基苯氧基乙酸酯衍生物、芳基氧基苯乙酸酯衍生物、一种或多种取代的喹啉，或其药学上可接受的盐、水合物或原药，或其组合，其用量和配方足以使寄生虫对药物敏感，用药物治疗寄生虫感染患者，或用药物预防寄生虫感染患者的症状。
• OPTICAL RECORDING COMPOSITION AND HOLOGRAPHIC RECORDING MEDIUM
  申请人：SUZUKI Hiroyuki

  公开号：US20090202921A1

  公开（公告）日：2009-08-13

  The present invention provides an optical recording composition comprising at least one compound denoted by general formula (I) and a holographic recording medium comprising a recording layer, wherein the recording layer comprises at least one compound denoted by general formula (I). In general formula (I), each of A 1 and A 2 independently denotes —CR 4 R 5 —, —O—, —NR 6 —, —S—, or —C(═O)—, each of R 4 , R 5 , and R 6 independently denotes a hydrogen atom or a substituent, R 1 denotes a substituent, n denotes an integer ranging from 0 to 4, each of R 2 and R 3 independently denotes a substituent having a Hammett substituent constant, σp value, of greater than 0, R 2 and R 3 do not form a ring structure by bonding together, and at least one from among R 1 , R 2 , R 3 , A 1 , and A 2 comprises at least one polymerizable group.
• COMPOSITIONS AND METHODS FOR INHIBITION OF MYCOBACTERIA
  申请人：Reddy Manchi CM

  公开号：US20170065601A1

  公开（公告）日：2017-03-09

  A composition comprising a drug selected from the group consisting of an arylphenoxypropionate derivative, an aryloxyphenoxyacetate derivative, an aryloxyphenylacetate derivative, a substituted quinol, or a salt, hydrate, or prodrugs thereof, or a combination thereof, in an amount and formulation sufficient to inhibit a mycobacterium is disclosed.